In From Managing Illness to Building Health , a just-released white paper, Noom Health outlines why a fragmented, condition-specific approach is structurally misaligned with both clinical science and financial outcomes and argues for a shift toward integrated, prevention-focused models that address root causes rather than downstream symptoms
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a cornerstone in the treatment of diabetes and obesity and have emerged as a promising option for other metabolic disorders, including hepatic steatosis
Cardiovascular Diabetology
Treatment is primarily supportive, including fluid resuscitation, pressors (dopamine, midodrine, etc.), pain management, wound cleaning, and infection prophylaxis/treatment
If you have type 2 diabetes and want tirzepatide, the FDA-approved option (Mounjaro) is specifically indicated for your condition and should be discussed with your endocrinologist
Simultaneously, GLP-1 suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production when it is not needed